To determine whether specific macrophage immune functions of the newly born are insensitive to the actions of therapeutic levels of dexamethasone (DEX), previously measured in infants with bronchopulmonary dysplasia (BPD), compared with betamethasone (BETA) and exogenous or endogenous interleukin-10 (IL-10). STUDY DESIGN: Macrophages were differentiated from cord blood monocytes (N ¼ 18). A serial dose-response (around 10 À 8 M), in vitro study was used to examine the effect of DEX, BETA and IL-10, on proinflammatory (PI) cytokine release, phagocytosis and respiratory burst. RESULT: Exogenous IL-10 (10 À 8 M) significantly (Po0.05) inhibited the endotoxin-stimulated release of IL-6, IL-8 and tumor necrosis factor by 63 to 82% with no significant effect by DEX and BETA. There was no inhibition by these three agents at 10 À 8 M on phagocytosis and respiratory burst. Inhibition of endogenous IL-10 with a monoclonal antibody significantly increased endotoxin-stimulated cytokine release by at least fourfold. CONCLUSION: Macrophages were relatively insensitive to therapeutic levels of DEX and BETA with regard to PI cytokine release. This study provides rationale for translational and preclinical research using airway instillation of IL-10 for the treatment of BPD.
INTRODUCTION
Bronchopulmonary dysplasia (BPD) is one of the most important causes of morbidity and mortality from neonatal intensive care units. 1 Persistent lung inflammation, with an imbalance of proinflammatory (PI) versus anti-inflammatory (AI) mediators, has a central role in the pathogenesis of BPD along with an arrest of lung growth. [2] [3] [4] [5] Late AI therapy with dexamethasone (DEX) has been the mainstay of therapy for neonates that are at high risk for severe BPD and/or death. 6 The optimal dose of postnatal DEX that reduces the incidence of BPD without increasing neurodevelopmental injury is not known, but appears to occur when higher cumulative doses of DEX are administered. 7 DEX treatment for BPD is only partially effective and may be associated with potential serious short-and long-term side effects, therefore alternative therapies are being actively investigated. 8, 9 During the early evolution of BPD, there are abnormally high levels of polymorphonuclear leukocytes followed by monocytes recruited into the lung. [10] [11] [12] [13] Circulating monocytes are the principal precursor of alveolar macrophages. 14 By 1 to 2 weeks after birth, the principal inflammatory cells in the airway fluid of babies with evolving BPD are macrophages-associated high levels of PI cytokines such as interleukin-6 (IL-6), IL-8 and tumor necrosis factor (TNF). 15 In contrast, the potent AI cytokine (IL-10) is either absent or detected at very low levels from airway fluid of babies developing BPD. [16] [17] [18] Interestingly, previous work has shown that the endotoxin-stimulated monocyte of the newborn, the cell precursor of the alveolar macrophage is insensitive to glucocorticoids compared with exogenous IL-10 on an equimolar basis, in the therapeutic dose range of DEX for BPD. 19, 20 Accordingly, we hypothesized that for the macrophages of the newly born: (1) endogenous and exogenous IL-10 produces a greater inhibition of PI cytokine release compared with equimolar levels of DEX and betamethasone (BETA); but (2) these three AI agents, at therapeutic levels of DEX for BPD, may have an unwanted inhibitory effect on two major macrophage innate immune functions, phagocytosis and respiratory burst.
METHODS Subjects
Cord blood (B60 ml) was obtained from placentas after elective, term cesarean section deliveries, without medical complications. Blood was collected in heparinized preservative-free tubes to be transported to the laboratory, followed by immediate cell isolation. The study was approved by the Internal Review Board of the North Shore-Long Island Jewish Health System, consent was not required.
Cell isolation and culture
Monocytes were isolated from cord blood as previously described 19, 20 with 495% viability by Trypan-blue inclusion and 490% (CD14 þ ) purity by flow cytometry. Briefly, peripheral blood mononuclear leukocytes (monocytes and lymphocytes) were isolated from cord blood using ficoll-paque plus (Amersham-GE Healthcare, Piscataway, NJ, USA) density centrifugation. Monocytes were separated from lymphocytes using percoll (Amersham-GE Healthcare) and the MACS monocyte isolation kit II supplemented with CD15 microbeads (Miltenyi Biotec, Auburn, CA, USA). Monocytes were resuspended in RPMI at 1 Â 10 6 cells per well. Monocytes were allowed to adhere for 1 h at 37 1C.
Macrophage differentiation
RPMI media was removed and adherent monocytes were reincubated at 37 1C þ 5% CO 2 with RPMI 1640 supplemented with penicillin-streptomycin, 10% fetal calf serum, glutamine and granulocyte macrophage colonystimulating factor (10 ng ml À 1 ) for 7 days. 21 Media was changed on day 4. Cells were examined histologically for differentiation using a Zeiss Apotome inverted microscope at Â 20 resolution (Carl Zeiss Microscopy, LLC, Thornwood, NY). At the time of each experiment, cell viability was assessed by the 3-(4,5-dimethylthiazol-2-yl)-diphenyl tetrazolium bromide assay.
Cytokine release and inhibition
Macrophages (N ¼ 6, cord blood samples) were preincubated for 1 h with phosphate buffered-saline (PBS) vehicle or serial concentrations of recombinant IL-10 (R&D Systems, Minneapolis, MN, USA), DEX or BETA (American Regent, Shirley, NY, USA). For the dose-response experiments, equimolar, serial doses of 10 À 10 to 10 À 6 M of these three agents were used, based on work demonstrating that the plasma concentration range of DEX in neonates being treated for BPD was 10 À 8 to 10 À 7 M. 22, 23 Macrophages were then stimulated with lipopolysaccharide (LPS, 1 ng ml À 1 in PBS; Sigma-Aldrich, St Louis, MO, USA) for 4 and18 h. PBS was used as a negative control. Separately, macrophages were incubated with anti-IL-10 antibody or IgG as a control (R&D Systems) before LPS stimulation to determine the effect of endogenous IL-10 on PI cytokine release. For the time course experiments (N ¼ 7), macrophages were preincubated with equimolar concentrations (10 À 8 M) of IL-10, DEX or BETA for 1 h, then stimulated with LPS (1 ng ml À 1 for 4 and 18 h. Cell culture supernatant was collected and analyzed for cytokine release of IL-6, IL-8 and TNFa using ELISA kits (R&D Systems).
Phagocytosis
Macrophage phagocytosis was measured by the CytoSelect 96-well Phagocytosis Zymosan Colorimetric Assay (Cell Biolabs, San Diego, CA, USA), according to the manufacturer's protocol. Briefly, monocytes (N ¼ 7, cord blood samples) were incubated in 96-well plates (5 Â 10 5 cells per per well) and differentiated into macrophages as described above. At 7 days, differentiated macrophages were preincubated for 1 h at 37 1C with 10 À 8 M IL-10, DEX or BETA, with PBS as a control. Cells were then stimulated with prelabeled zymosan (5 Â 10 6 particles per well) for 2 h. Engulfed zymosan was detected at an absorbance of 405 nm.
Respiratory burst
Monocytes (N ¼ 5, cord blood samples; 10 5 cells per well) were incubated in black, clear bottom 96-well plates and differentiated into macrophages as described above. Macrophage respiratory burst was measured using the OxiSelect intracellular ROS assay kit (Cell Biolabs, San Diego, CA, USA). Differentiated macrophages were washed with PBS and preincubated for 1 h at 37 1C with 10 À 8 M IL-10, DEX or BETA, with PBS as a control. At 30 min, cell-permeable fluorogenic probe 2',7'-dichlorohydrofluoroescin diacetate was added to the cell media. After 1 h, cells were washed and stimulated with zymosan A from Saccharomyces cerevisiae (0.5 mg ml À 1 ; Sigma-Aldrich). Cells incubated with hydrogen peroxide served as a positive control during the assay. The DCFH oxidized to highly fluorescent 2 0 7 0 -dichlorohydrofluoroscein by reactive oxygen species generated during the incubation with zymosan was read at 0 h (baseline) and 1 h, using a fluorescent plate reader with 480 nm excitation and 530 nm emission.
Statistical analysis
Data were analyzed by one-way analysis of variance with a Bonferroni correction for multiple comparisons over time, between concentrations of inhibitors and for the effects of IL-10 and glucocorticoids on phagocytosis and respiratory burst. An overall P-value of 0.05 was considered statistically significant. Figure 1 demonstrates the effect of serial increase in DEX on release of three PI cytokines over 18 h from endotoxin-stimulated macrophages of the newborn. The only significant inhibition was observed for IL-8 release when macrophages were pretreated with DEX at 10 À 6 M. Figure 2 demonstrates the results of the same dose-response design for BETA. However, a significant inhibition of IL-8 and TNFa was observed at 10 À 7 M. Figure 3 demonstrates the effect of serial increases of IL-10 on the same three cytokines released from endotoxin-stimulated macrophages of the newborn over 18 h. Release of all three cytokines were inhibited by over 50% with IL-10 at 10 À 10 M and with further inhibition occurred to over 80% with 10 À 8 M. In addition, this figure demonstrates the effect of pretreatment of endotoxin-stimulated macrophages with a monoclonal antibody to IL-10 (IL-10 mAb) and IgG as a control. Over a fivefold increase in cytokine release was observed over 18 h for each cytokine with preincubation of macrophages with IL-10 mAb before LPS stimulation. There was no effect of preincubation of IgG (as a control for IL-10 mAb) on the release of these cytokines compared with endotoxin alone. The time-related effects of equimolar levels (10 À 8 M) of DEX, BETA and exogenous IL-10 on LPS-stimulated macrophages (10 6 cells) release for three PI cytokines are shown in Figure 4 . Cytokine levels at 4 and 18 h of LPS stimulation with an AI agent were compared with cells exposed to LPS alone. DEX had no effect on any cytokine release. BETA inhibited IL-8 release by 25% at 18 h. Exogenous IL-10 inhibited the release of all three cytokines at 4 h (IL-6 by 84%, IL-8 by 74% and TNF by 64%). At 18 h, exogenous IL-10 inhibited the release of the three PI cytokines (IL-6 by 82%, IL-8 by 72% and TNF by 83%).
RESULTS
There was no effect of 10 À 8 M DEX, BETA or IL-10 on phagocytosis as shown in Figure 5 . A marked effect was observed with cytochalasin D. There was also no effect of 10 À 8 M DEX, BETA or IL-10 on respiratory burst as shown in Figure 6 . Zymosan alone produced a significant increase in superoxide release as measured by 2 0 7 0 -dichlorohydrofluoroscein.
DISCUSSION
The present study used macrophages derived from cord blood of the newly born, to compare the effect of equimolar levels of exogenous IL-10 versus DEX and BETA on PI cytokine release, phagocytosis and respiratory burst. At plasma levels of DEX detected in babies being treated for BPD (B10 À 8 M), only IL-10 produced a significant reduction in PI cytokine release and there was no effect of these three agents on phagocytosis and respiratory burst.
By 10 days after birth in the evolution of BPD, macrophages are the principal cells found within the airway fluid and the major source of PI cytokines. 15 IL-10, the potent AI cytokine, can be produced by MONOs and macrophages but not by polymorphonuclear leukocytes of the newborn. 24 However, IL-10 is absent or found at very low levels in the airway fluid of babies with evolving BPD suggesting an imbalance in PI and AI cytokines as one underlying mechanism of this disorder [16] [17] [18] MONOs, the principal precursors of alveolar macrophages of the newborn, demonstrate a striking insensitivity to DEX compared with IL-10 at therapeutic levels of DEX. 20 In the present study, under similar experimental conditions in previous monocyte studies, we found a similar glucocorticoid insensitivity observed in macrophages of the newborn. This insensitivity may explain, in part, why the beneficial AI effect of exogenous DEX in present day treatment of BPD is only partly effective. 6 Corticosteroid insensitivity has been reported in several common and serious adult pulmonary disorders, including chronic obstructive pulmonary disease and severe asthma. 25 Patients with asthma, who also smoke, are insensitive to corticosteroids. 25 Research directed to mononuclear cells and macrophages have started to uncover mechanisms associated with corticosteroid insensitivity. [25] [26] [27] [28] Owing to the harmful side effects and limited efficacy of corticosteroids, alternative therapy for BPD is needed. Novel AI therapy for the prevention or treatment of BPD should be selective in its effect on immune functions of the newborn, so as to minimize the risk of the newborn to infection. We found that IL-10 at 10 À 8 M resulted in marked inhibition of PI cytokine release in macrophages unlike the corticosteroids. Neither IL-10, DEX nor BETA had significant effects on the important macrophage functions of phagocytosis and respiratory burst. In previous work IL-10 was found to be a deactivator or activator of phagocytosis depending on the neutrophil or monocyte cell type from adults and also on the concentration of IL-10. 29 In mouse peritoneal macrophages, glucocorticoids enhanced the respiratory burst via a nongenomic mechanism. 30 The present in vitro studies used clinical benchmarks for LPS stimulation and the testing of equimolar levels of the three AI agents on macrophage functions. LPS was used at a concentration of 1 ng ml À 1 to benchmark against levels found in amniotic fluid during the fetal inflammatory response syndrome (0.6 to 48 ng ml À 1 ). 31 Measurements of plasma DEX levels during the treatment of BPD were in the 10 À 7 to 10 À 8 M range in an era when relatively higher doses of DEX were used to treat BPD on a long tapering dose regimen. 22, 23 All dose comparisons in the present study for IL-10, DEX and BETA were made on an equimolar basis. Among the many PI cytokines found in airway fluid of babies with evolving BPD, IL-6 and IL-8 are found at the highest levels by 10 days. 15, 16 No significant inhibition of these PI cytokines was observed at 10 À 8 M by DEX and BETA. IL-1b has also been found in the airway of neonates developing BPD; 15, 16 however, interestingly, we could not detect IL-1b under our experimental conditions (data not shown). Other investigators have found variable production of IL-1b by macrophages. 32 A limitation of this study may be the use of cord blood from healthy term infants after elective cesarean section, as BPD occurs more frequently in preterm infants after respiratory distress syndrome than term infants with hypoxic respiratory failure. 1, 33 The design for the present study required the collection of enough volume of blood for monocyte isolation. The design also avoided the potential confounding effects of antenatal steroids, maternal medications and maternal disorders associated with prematurity that are not present when corticosteroids are used for BPD, usually beyond several weeks after birth. 34 This study does not address whether there are developmental differences in macrophage insensitivity to glucocorticoids or to IL-10. Additionally, we chose to use in vitro differentiation of monocytes to study macrophages because alveolar macrophages of the premature infants could not provide enough cells to perform the present studies. However, cell surface antigens and functions of granulocyte macrophage colony-stimulating factor-induced, monocyte-derived macrophages from adults have almost identical characteristics as alveolar macrophages from adults. 21 In conclusion, the present in vitro study demonstrates a relative insensitivity of DEX, and to a lesser degree BETA, with regard to PI cytokine release from monocyte-derived macrophages of the newly born, compared with equimolar levels of IL-10. These findings may help explain why DEX, when used at a low dose and short course, for selected patients with advanced BPD, has limited efficacy. 34, 35 None of these three agents had an inhibitory effect on macrophage respiratory burst or phagocytosis, which may have a role in the pathogenesis of BPD, at equimolar therapeutic levels of DEX. The relatively selective effect of these three agents on PI cytokine release from macrophages of the newborn could tip the balance of inflammation toward recovery without jeopardizing the newborn to infection. IL-10 has been used to treat adults with chronic inflammatory disorders. 36 Therefore, the present study provides rationale for translational research using airway instillation of IL-10 as potential therapy for BPD, in a manner similar to preclinical and clinical work for surfactant laced with budesonide. 37 
